291 related articles for article (PubMed ID: 9708225)
41. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
[TBL] [Abstract][Full Text] [Related]
42. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
Watts NB; Harris ST; Genant HK; Wasnich RD; Miller PD; Jackson RD; Licata AA; Ross P; Woodson GC; Yanover MJ
N Engl J Med; 1990 Jul; 323(2):73-9. PubMed ID: 2113611
[TBL] [Abstract][Full Text] [Related]
43. Predicting subsequent bone density response to intermittent cyclical therapy with etidronate from initial density response in patients with osteoporosis.
Crilly RG; Sebaldt RJ; Hodsman AB; Adachi JD; Brown JP; Goldsmith CH; Hanley DA; Olszynski WO; Ste-Marie LG; Stephenson GF
Osteoporos Int; 2000; 11(7):607-14. PubMed ID: 11069195
[TBL] [Abstract][Full Text] [Related]
44. Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied?
van der Goes MC; Jacobs JW; Jurgens MS; Bakker MF; van der Veen MJ; van der Werf JH; Welsing PM; Bijlsma JW
Osteoporos Int; 2013 Apr; 24(4):1429-36. PubMed ID: 23011680
[TBL] [Abstract][Full Text] [Related]
45. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
van Bodegraven AA; Bravenboer N; Witte BI; Dijkstra G; van der Woude CJ; Stokkers PC; Russel MG; Oldenburg B; Pierik M; Roos JC; van Hogezand RA; Dik VK; Oostlander AE; Netelenbos JC; van de Langerijt L; Hommes DW; Lips P;
Gut; 2014 Sep; 63(9):1424-30. PubMed ID: 24146170
[TBL] [Abstract][Full Text] [Related]
46. Calcitriol does not prevent bone loss in patients with asthma receiving corticosteroid therapy: a double-blind placebo-controlled trial.
McDonald CF; Zebaze RM; Seeman E
Osteoporos Int; 2006 Oct; 17(10):1546-51. PubMed ID: 16832714
[TBL] [Abstract][Full Text] [Related]
47. The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment.
Montessori ML; Scheele WH; Netelenbos JC; Kerkhoff JF; Bakker K
Osteoporos Int; 1997; 7(1):52-8. PubMed ID: 9102064
[TBL] [Abstract][Full Text] [Related]
48. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up).
Meunier PJ; Confavreux E; Tupinon I; Hardouin C; Delmas PD; Balena R
J Clin Endocrinol Metab; 1997 Sep; 82(9):2784-91. PubMed ID: 9284696
[TBL] [Abstract][Full Text] [Related]
49. Clodronate is effective in preventing corticosteroid-induced bone loss among asthmatic patients.
Herrala J; Puolijoki H; Liippo K; Raitio M; Impivaara O; Tala E; Nieminen MM
Bone; 1998 May; 22(5):577-82. PubMed ID: 9600795
[TBL] [Abstract][Full Text] [Related]
50. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
[TBL] [Abstract][Full Text] [Related]
51. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
52. Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial.
Lindor KD; Jorgensen RA; Tiegs RD; Khosla S; Dickson ER
J Hepatol; 2000 Dec; 33(6):878-82. PubMed ID: 11131448
[TBL] [Abstract][Full Text] [Related]
53. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis.
Reginster JY; Kuntz D; Verdickt W; Wouters M; Guillevin L; Menkès CJ; Nielsen K
Osteoporos Int; 1999; 9(1):75-81. PubMed ID: 10367032
[TBL] [Abstract][Full Text] [Related]
54. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
Sambrook PN; Roux C; Devogelaer JP; Saag K; Lau CS; Reginster JY; Bucci-Rechtweg C; Su G; Reid DM
Bone; 2012 Jan; 50(1):289-95. PubMed ID: 22061864
[TBL] [Abstract][Full Text] [Related]
55. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis.
Storm T; Kollerup G; Thamsborg G; Genant HK; Sørensen OH
J Rheumatol; 1996 Sep; 23(9):1560-4. PubMed ID: 8877926
[TBL] [Abstract][Full Text] [Related]
56. Bone loss after heart transplant: effect of alendronate, etidronate, calcitonin, and calcium plus vitamin D3.
Gilfraguas L; Guadalix S; Martinez G; Jodar E; Vara J; Gomez-Sanchez MA; Delgado J; De La Cruz J; Lora D; Hawkins F
Prog Transplant; 2012 Sep; 22(3):237-43. PubMed ID: 22951500
[TBL] [Abstract][Full Text] [Related]
57. Beneficial effect of intermittent cyclical etidronate therapy in hemiplegic patients following an acute stroke.
Sato Y; Asoh T; Kaji M; Oizumi K
J Bone Miner Res; 2000 Dec; 15(12):2487-94. PubMed ID: 11127214
[TBL] [Abstract][Full Text] [Related]
58. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
Cheung AM; Tile L; Cardew S; Pruthi S; Robbins J; Tomlinson G; Kapral MK; Khosla S; Majumdar S; Erlandson M; Scher J; Hu H; Demaras A; Lickley L; Bordeleau L; Elser C; Ingle J; Richardson H; Goss PE
Lancet Oncol; 2012 Mar; 13(3):275-84. PubMed ID: 22318095
[TBL] [Abstract][Full Text] [Related]
59. Use of risedronate to prevent bone loss following a single course of glucocorticoids: findings from a proof-of-concept study in inflammatory bowel disease.
Kriel MH; Tobias JH; Creed TJ; Lockett M; Linehan J; Bell A; Przemioslo R; Smithson JE; Brooklyn TN; Fraser WD; Probert CS
Osteoporos Int; 2010 Mar; 21(3):507-13. PubMed ID: 19484170
[TBL] [Abstract][Full Text] [Related]
60. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.
Storm T; Thamsborg G; Steiniche T; Genant HK; Sørensen OH
N Engl J Med; 1990 May; 322(18):1265-71. PubMed ID: 2109197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
